

# Kallikrein Inhibitor - Pipeline Insight, 2022

<https://marketpublishers.com/r/KB903539E23EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: KB903539E23EN

## Abstracts

This report can be delivered to the clients within 2-3 working days

DelveInsight's, "Kallikrein Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Kallikrein Inhibitor - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Kallikrein Inhibitor - Pipeline Insights, 2021 Understanding

#### Kallikrein Inhibitor - Pipeline Insights, 2021: Overview

Plasma prekallikrein is the liver-derived precursor of the trypsin-like serine protease plasma kallikrein, and circulates in plasma bound to high molecular weight kininogen. Plasma prekallikrein is activated to plasma kallikrein by activated factor XII or prolylcarboxypeptidase. Plasma kallikrein regulates the activity of multiple proteolytic cascades in the cardiovascular system such as the intrinsic pathway of coagulation, the kallikrein-kinin system, the fibrinolytic system, the renin-angiotensin system, and the complement pathways. As such, plasma kallikrein plays a central role in the pathogenesis of thrombosis, inflammation, and blood pressure regulation. Under physiological conditions, plasma kallikrein serves as a cardioprotective enzyme. However, its increased plasma concentration or hyperactivity perpetuates

cardiovascular disease (CVD).

'Kallikrein Inhibitor - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kallikrein Inhibitor - Pipeline Insights, 2021 pipeline landscape is provided which includes the disease overview and Kallikrein Inhibitor - Pipeline Insights, 2021 treatment guidelines. The assessment part of the report embraces, in depth Kallikrein Inhibitor - Pipeline Insights, 2021 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kallikrein Inhibitor - Pipeline Insights, 2021 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Kallikrein Inhibitor - Pipeline Insights, 2021 R&D. The therapies under development are focused on novel approaches to treat/improve Kallikrein Inhibitor - Pipeline Insights, 2021.

### Kallikrein Inhibitor - Pipeline Insights, 2021 Emerging Drugs Chapters

This segment of the Kallikrein Inhibitor - Pipeline Insights, 2021 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Kallikrein Inhibitor - Pipeline Insights, 2021 Emerging Drugs

#### THR-149: Oxurion

THR-149 is a plasma kallikrein (PKal) inhibitor for treatment of DME. Through the inhibition of the plasma kallikrein-kinin (PKal-kinin) system, THR-149 prevents the induction of retinal vascular permeability, inflammation and angiogenesis. Literature data show that patients with DME have elevated levels of plasma kallikrein and that the

vitreous level of plasma kallikrein varies less compared to VEGF, making it a potentially more effective target for treating DME. Oxurion has reported positive topline phase 1 results for the clinical study evaluating THR-149 for the treatment of DME. It is currently in Phase II stage of development.

#### Donidalorsen: Ionis Pharmaceuticals

Donidalorsen, formerly known as IONIS-PKK-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of prekallikrein, or PKK, to treat patients with hereditary angioedema, or HAE. PKK plays an important role in the activation of inflammatory mediators associated with acute attacks of HAE. HAE is a rare genetic disease characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea. However, current prophylactic treatment approaches are very limited and have major tolerability issues due to challenging administration requirements leaving patients with few therapeutic options. It is currently in Phase II stage of development.

Further product details are provided in the report.....

#### Kallikrein Inhibitor - Pipeline Insights, 2021: Therapeutic Assessment

This segment of the report provides insights about the different Kallikrein Inhibitor - Pipeline Insights, 2021 drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Kallikrein Inhibitor - Pipeline Insights, 2021

There are approx. 13+ key companies which are developing the therapies for Kallikrein Inhibitor - Pipeline Insights, 2021. The companies which have their Kallikrein Inhibitor - Pipeline Insights, 2021 drug candidates in the most advanced stage, i.e. Phase II include, Oxurion.

#### Phases

DelveInsight's report covers around 13+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Kallikrein Inhibitor - Pipeline Insights, 2021 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Kallikrein Inhibitor - Pipeline Insights, 2021: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Kallikrein Inhibitor - Pipeline Insights, 2021 therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kallikrein Inhibitor - Pipeline Insights, 2021 drugs.

Kallikrein Inhibitor - Pipeline Insights, 2021 Report Insights

Kallikrein Inhibitor - Pipeline Insights, 2021 Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Kallikrein Inhibitor - Pipeline Insights, 2021 Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Kallikrein Inhibitor - Pipeline Insights, 2021 drugs?

How many Kallikrein Inhibitor - Pipeline Insights, 2021 drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Kallikrein Inhibitor - Pipeline Insights, 2021?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Kallikrein Inhibitor - Pipeline Insights, 2021 therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Kallikrein Inhibitor - Pipeline Insights, 2021 and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Oxurion

Intellia Therapeutics

Ionis Pharmaceuticals

KalVista Pharmaceuticals

Astria Therapeutics

### Key Products

THR-149

NTLA2002

KVD-824

Donidalorsen

JNJ-78278343

STAR-0215

## Contents

Introduction

Executive Summary

Kallikrein Inhibitor - Pipeline Insights, 2021: Overview

- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

- Comparative Analysis

Drug Name: Company Name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

THR-149: Oxurion

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early stage products (Phase I)

- Comparative Analysis

JNJ-78278343: Janssen Research & Development

- Product Description
- Research and Development
- Product Development Activities



Drug profiles in the detailed report.....

Preclinical stage products

- Comparative Analysis

STAR-0215: Astria Therapeutics

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Kallikrein Inhibitor - Pipeline Insights, 2021 Key Companies

Kallikrein Inhibitor - Pipeline Insights, 2021 Key Products

Kallikrein Inhibitor - Pipeline Insights, 2021- Unmet Needs

Kallikrein Inhibitor - Pipeline Insights, 2021- Market Drivers and Barriers

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Kallikrein Inhibitor - Pipeline Insights, 2021

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Kallikrein Inhibitor - Pipeline Insights, 2021

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Kallikrein Inhibitor - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/KB903539E23EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/KB903539E23EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970